Testing BHV-1300 for treating Graves' Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of BHV-1300 in individuals diagnosed with Graves' Disease, an autoimmune condition that leads to hyperthyroidism. Participants will receive the intervention to assess its impact on their condition. The study aims to gather data on how well BHV-1300 works in managing the symptoms and underlying causes of Graves' Disease. It is a Phase 1 interventional trial, focusing on a specific patient population with active hyperthyroidism.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1\. Participants must have serologically confirmed Graves' Disease.

Key Exclusion Criteria:

1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit.
2. History of treatment with radioactive iodine or thyroid surgery.

Where it's running

• Site-103
  South Gate, California, United States Recruiting
• Site-100
  Miami, Florida, United States Recruiting
• Site-104
  Columbus, Georgia, United States Recruiting
• Site-108
  Greenville, North Carolina, United States Recruiting
• Site-110
  Canton, Ohio, United States Recruiting
• Site-107
  Memphis, Tennessee, United States Recruiting

Study contacts

• Study coordinator: Chief Medical Officer
• Email: clinicaltrials@biohavenpharma.com
• Phone: 203-404-0410

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Efgartigimod for Graves' Disease in adults

  We are testing if efgartigimod given under the skin can help adults with Graves' disease by improving thyroid function and whether it is safe and tolerable.

  Recruiting at 35 sites Phase 3 argenx · Carlsbad, California and 34 other locations · NCT07570316

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Early risk stratification of thyroid eye disease in newly diagnosed Graves' disease

  This study tests whether early eye-related signs, blood and tear biomarkers, or eye surface features can predict who with Graves’ disease will develop thyroid eye disease within a year.

  Recruiting University of Copenhagen · Herlev · NCT07812194

• Felzartamab for Graves’ Disease: See if it helps control thyroids and reduce need for ATDs

  This study tests felzartamab vs placebo in adults with Graves’ disease to see if it can normalize thyroid hormones and let people stop anti-thyroid drugs.

  Recruiting at 14 sites Phase 2 Biogen · Glendale, Arizona and 13 other locations · NCT07722546

• AI-based MRI and ultrasound for thyroid-related eye disease

  This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.

  Recruiting Shanghai Changzheng Hospital · Shanghai, Huangpu District · NCT07716397

• YB-101 for Graves' Disease: safety, dosing, and how it works

  This study tests YB-101 versus placebo in adults with Graves' disease to see if it is safe, tolerated, and whether it can help thyroid symptoms over about 40 weeks.

  Recruiting at 25 sites Phase 2 Yarrow Bioscience, Inc. · Gilbert, Arizona and 31 other locations · NCT07682896

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.